GLP-1 Compounder Study Reveals Troubling Findings

A study examining the market for compounded GLP-1 drugs has uncovered troubling findings regarding the quality and safety of these preparations. Despite the resolution of shortages for branded semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), the market for compounded versions has persisted. Many compounding pharmacies have continued to add ingredients such as B vitamins to these formulations. The study, published in the Journal of the American Medical Association (JAMA) Internal Medicine on May 21, 2024, investigated 30 different compounded GLP-1 products obtained from 17 pharmacies across 12 states.

The research team found that 100% of the tested compounded semaglutide products contained semaglutide, but only 4% met the USP monograph for semaglutide. Furthermore, 100% of the tested compounded tirzepatide products contained tirzepatide, with 100% meeting the USP monograph for tirzepatide. However, the presence of undeclared ingredients was a significant concern. The study identified undeclared ingredients in 100% of the compounded semaglutide products and 77% of the compounded tirzepatide products. These undeclared substances included various B vitamins, such as cyanocobalamin and pyridoxine hydrochloride, and in one instance, a peptide not listed on the product label.

These findings raise serious questions about the consistency, purity, and safety of compounded GLP-1 drugs. The addition of unlisted ingredients, particularly in medications intended for chronic use, could lead to unforeseen side effects or interactions with other medications. The USP (United States Pharmacopeia) monograph provides standards for the identity, strength, quality, and purity of medicines. The low adherence to these standards by compounded semaglutide products is particularly concerning.

The study's authors, led by Dr. Amelia Vance of the University of Michigan, emphasized the need for greater regulatory oversight and transparency in the compounding pharmacy sector, especially concerning popular weight-loss medications. The continued demand for GLP-1 agonists, driven by their efficacy in weight management and treatment of type 2 diabetes, has fueled the growth of the compounding market. However, this demand should not come at the expense of patient safety and product integrity. The researchers recommend that prescribers and patients exercise caution when considering compounded GLP-1 drugs and prioritize FDA-approved formulations when available and appropriate.